Page last updated: 2024-08-21

fluorobenzenes and Dyslipidemia

fluorobenzenes has been researched along with Dyslipidemia in 106 studies

Research

Studies (106)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	29 (27.36)	29.6817
2010's	77 (72.64)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bae, J; Kryzhanovski, VA; LeNarz, LA; Sponseller, CA; Zhao, Z; Zhu, Y	1
Elisaf, M; Kei, A; Liberopoulos, EN; Mikhailidis, DP	1
Kangwanvanich, S; Permpongkosol, S	1
Elisaf, M; Kei, A; Liberopoulos, E; Rizzo, M; Tellis, K; Tselepis, A	1
Barter, PJ; Karlson, BW; Lundman, P; Nicholls, SJ; Palmer, MK	1
Goto, SN; Mizuno, Y; Niwa, M; Takagi, H; Umemoto, T; Yamamoto, H	1
Camacho, X; Carter, AA; Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR	1
Arayne, MS; Sultana, N; Tabassum, A	1
Burns, KM; Carlson, DM; Kelly, MT; Lele, A; Setze, CM; Stolzenbach, JC; Weinstein, DL; Williams, LA	1
Elisaf, M; Kei, A; Liberopoulos, E; Tellis, C; Tselepis, A	2
Reiner, Ž; Tedeschi-Reiner, E	1
Black, CA; Fleming, JW; Malinowski, SS; Miller, KH; Riche, DM; Wofford, MR	1
Foody, JM; Hu, H; Neff, D; Ramey, DR; Sajjan, S; Tershakovec, AM; Tomassini, JE; Toth, PP; Tunceli, K	1
Barrett, PH; Chan, DC; Hamilton, SJ; Pang, J; Tenneti, VS; Watts, GF	1
DiNicolantonio, JJ; Elisaf, MS; Liberopoulos, EN; Rizos, CV; Tellis, K; Tselepis, AD	1
Abraham, SJ; Ganesh, JS; Iwasaki, M; Jayakrishnan, GA; Preethy, S; Rao, YY; Ravikumar, R	1
Andy Schuetz, C; Folse, H; Gandhi, S; Rengarajan, B; Sternhufvud, C	1
Izuhara, M; Matsuda, M; Mitsuoka, H; Shioji, K; Uegaito, T	1
Arnaoutoglou, EM; Kouvelos, GN; Matsagkas, MI; Milionis, HJ; Papa, N; Raikou, VD	1
Akhlaghi, F; Asberg, A; Ghareeb, M; Granseth, T; Holdaas, H; Midtvedt, K; Molden, E; Reier-Nilsen, M; Robertsen, I; Vethe, NT	1
Campese, VM	1
Kakuda, H; Matoba, M; Nagao, S; Nakatoh, H; Takekoshi, N	1
Higa, M; Ichijo, T; Katabami, T; Kobayashi, S; Matsui, T; Murakami, M; Ohta, A; Takagi, S; Tanaka, Y; Ujihara, M	1
Arneja, J; Shah, SN	1
Fialkow, J; Legg, JC; Nedergaard, BS; Nelson, P; Neutel, JM; Ramstad, D; Robinson, JG; Rogers, WJ; Scott, R; Somaratne, R; Wasserman, SM; Weiss, R	1
Deguchi, I; Fukuoka, T; Hayashi, T; Horiuchi, Y; Kato, Y; Maruyama, H; Nagamine, Y; Ohe, Y; Sano, H; Sehara, Y; Tanahashi, N	1
Kuwano, T; Miura, S; Saku, K; Shimizu, T; Tanigawa, H; Uehara, Y; Zhang, B	1
Galeeva, ZM; Galiavich, AS	1
Chen, Y; Fan, Y; Jiang, C; Liu, F; Liu, M	1
Barter, PJ; Brewer, HB; Ford, J; Hovingh, GK; Kastelein, JJ; Rader, DJ; Round, P; Saleheen, D; van Deventer, SJ	1
Ray, KK; Vallejo-Vaz, AJ	1
Mearns, BM	1
Bain, AM; Busti, AJ; Rahman, AP; Rutherford, WS; White, EA	1
Birmingham, BK; Kung, LP; Martin, PD; Mitchell, PD; Schneck, DW; Tzeng, TB; Zhang, H	1
Bays, HE; Buttler, SM; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC	1
Buttler, SM; Davidson, MH; Jones, PH; Kashyap, ML; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC	1
Hsia, J; Otvos, JD; Rosenson, RS	1
Coppola, JT; DeVoe, MC; Gupta, RP; Hermance, EV; Mindrescu, C; Soma, VR; Staniloae, CS	1
Gentile, M; Marotta, G; Rubba, P	1
Aslangul, E; Assoumou, L; Bittar, R; Boccara, F; Bonnefont-Rousselot, D; Costagliola, D; Fiévet, MH; Giral, P; Kalmykova, O; Melchior, JC; Peytavin, G; Valantin, MA	1
Bologa, R; Cheigh, J; Gordon, B; Lanto, A; Levine, D; Parker, T; Rubin, A; Stenzel, K	1
Kelly, MT; Kipnes, MS; Lele, A; Rhyne, JM; Roth, EM; Setze, CM; Sleep, DJ; Stolzenbach, JC	1
Adeli, K; Dong, B; Kraemer, FB; Li, H; Liu, J; Park, SW; Seidah, NG; Wu, M	1
Elisaf, MS; Kostapanos, MS; Milionis, HJ	1
Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K	1
Hayashi, J; Hayashi, S; Maeda, S; Ohnishi, H; Sawayama, Y	1
Genest, J; Glynn, RJ; Hsia, J; MacFadyen, JG; Mora, S; Ridker, PM	1
Briseño, GG; Mino-León, D	1
Lakhani, A	1
Dervenoulas, J; Economopoulos, T; Economopoulou, C; Papageorgiou, S; Pappa, V; Tountas, N; Tsirigotis, P; Vrettos, I	1
Fujimori, S; Kaneko, K; Ogata, N; Oka, Y	1
Blasetto, JW; Carlson, DM; Fukumoto, SM; Khurmi, NS; Rosenson, RS; Roth, EM; Setze, CM; Stolzenbach, JC; Williams, LA	1
Carlson, DM; Gold, A; Jacobson, TA; Kelly, MT; Pepine, CJ; Setze, CM; Stolzenbach, JC; Williams, LA	1
Bastien, NR; Francis, GA; Genest, JJ; Goodman, SG; Langer, A; Leiter, LA; McPherson, R	1
Eisenberg, T; Wells, MT	1
Biron, P; Rose, CP; Vos, E	1
Carlson, DM; Hirshberg, B; Kelly, MT; Rosenson, RS; Setze, CM; Stolzenbach, JC; Williams, LA	1
Crane, HM; Crane, PK; Harrington, RD; Kitahata, MM; Knopp, RH; Kosel, BW; Mugavero, MJ; Saag, MS; Singh, S; Willig, JH	1
Agouridis, AP; Elisaf, MS; Filippatos, TD; Tselepis, AD; Tsimihodimos, V	1
Bárcena, R; Fortún, J; Graus, J; Moreno, A; Moreno, S; Nuño, J; Pérez-Elías, MJ; Quereda, C; Rodriguez-Gandía, MA; Wikman, P	1
Kelly, MT; Mohiuddin, SM; Setze, CM; Thakker, KM	1
Citkowitz, E	1
Burger, DM; de Kanter, CT; Keuter, M; Koopmans, PP; van der Lee, MJ	1
Anagnostis, P; Athyros, VG; Karagiannis, A; Kita, M; Mikhailidis, DP; Panagiotidou, A; Panagiotou, A; Polyzos, SA; Selalmatzidou, D; Slavakis, A	1
Al-Khateeb, A; Ibrahim, S; Imran, K; Mohamed, MS; Yusof, Z; Zilfalill, BA	1
Agouridis, AP; Dimitriou, AA; Elisaf, MS; Filippatos, TD; Mikhailidis, DP; Tellis, CC; Tselepis, AD; Tsimihodimos, V	1
Catapano, AL; Norata, GD; Pirillo, A	1
Kim, H; Kim, YK; Park, JB; Rhee, EJ; Rosenson, RS; Sung, KC	1
Hidaka, H; Hongo, M; Ikeda, U; Izawa, A; Kinoshita, O; Kumazaki, S; Tomita, T; Yazaki, Y	1
Dayspring, TD; Toth, PP	1
Brewer, HB; Hu, B; Kastelein, JJ; Krueger, KA; McErlean, E; Nicholls, SJ; Nissen, SE; Shao, M; Wang, MD	1
Davidson, MH; Ferdinand, KC; Kelly, MT; Setze, CM	1
Agouridis, AP; Challa, A; Elisaf, M; Liberopoulos, EN; Makariou, SE	1
Filippatos, TD	1
Connolly, M; Murad, AA; Tobin, AM	1
Aslangul, E; Assoumou, L; Bittar, R; Bonnefont-Rousselot, D; Cherfils, C; Costagliola, D; Federspiel, MC; Giral, P; Kalmykova, O; Valantin, MA	1
Ban, MR; Hegele, RA; Rahalkar, AR	1
Ballantyne, CM; Belmont, JW; Brautbar, A; Keinan, A; Ma, L	1
Agouridis, AP; Bairaktari, ET; Elisaf, MS; Kostapanos, MS; Kostara, C; Mikhailidis, DP; Tselepis, AD; Tsimihodimos, V	1
Alvarez Sanz, C; Barrios, V; Brosa, M; Capel, M; Lobos, JM; Serrano, A	1
Barrios, V; Escobar, C	1
Cunha, RV; Domingos, H; Domingos, JA; Paniago, AM; Rodrigues, RL; Souza, AS	1
Barkas, F; Elisaf, MS; Liamis, G; Liberopoulos, EN; Moutzouri, E; Rizos, CV	1
Cheng, YH; Lai, SW; Liao, KF; Lin, CL; Sung, FC	1
Adeli, K; Cheung, RC; Chong, T; Federico, L; Naples, M; Smith, GJ; Taylor, D	1
Chen, J; Li, D; Mehta, JL; Schaefer, R	1
Ivleva, AIa	1
Ahmed, MH	2
Davidson, M	1
Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V	1
De Hert, M; Hanssens, L; Kalnicka, D; Peuskens, J; Scheen, A; Van Eyck, D; van Winkel, R; Wampers, M	1
Blasetto, J; Harris, S; Miller, E; Shepherd, J; Vidt, DG	1
Balligand, JL; Davey, PC; De Keyzer, D; Desjardins, F; Geeraert, B; Herregods, MC; Holvoet, P; Mertens, A; Smith, G; Verreth, W	1
Chadarevian, R; Danchin, N; Gayet, JL; Licour, M; Valensi, P	1
Chazova, IE; Kaminnaia, VI; Kukharchuk, VV; Ratova, LG	1
Elisaf, M; Gazi, IF; Kalogirou, M; Kostapanos, M; Saougos, VG; Tambaki, AP; Tselepis, AD; Wolfert, RL	1
Bairaktari, ET; Elisaf, MS; Filippatos, TD; Kostapanos, MS; Milionis, HJ; Nakou, ES; Tselepis, AD	1
Afacan, B; Coban, E	1
Bennett, MT; Bondy, GP; Johns, KW	1
Hostalek, U; Kassner, U; Steinhagen-Thiessen, E; Vogt, A	1
Balligand, JL; De Keyzer, D; Desjardins, F; Herregods, MC; Holvoet, P; Mertens, A; Pelat, M; Sekkali, B; Smith, G; Verreth, W	1
García-Moll, X	1
Alvarez-Aguilar, C; Gómez-García, A; Martínez Torres, G; Ortega-Pierres, LE; Rodríguez-Ayala, E	1
Hansen, LB; Miller, AE; Saseen, JJ	1

Reviews

13 review(s) available for fluorobenzenes and Dyslipidemia

Article	Year
Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: a meta-analysis of randomized trials. Heart and vessels, 2014, Volume: 29, Issue:3 Topics: Atorvastatin; Biomarkers; Chi-Square Distribution; Down-Regulation; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Particle Size; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2014
Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs. Clinical and experimental nephrology, 2014, Volume: 18, Issue:2 Topics: Acute Kidney Injury; Atorvastatin; Disease Progression; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides	2014
A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature. Pharmacotherapy, 2008, Volume: 28, Issue:7 Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dyslipidemias; Fluorobenzenes; HIV Infections; Humans; Hypolipidemic Agents; Male; Middle Aged; Nevirapine; Patient Compliance; Pyrimidines; Reverse Transcriptase Inhibitors; Rosuvastatin Calcium; Sulfonamides	2008
Efficacy and safety of rosuvastatin in the management of dyslipidemia. Vascular health and risk management, 2009, Volume: 5, Issue:1 Topics: Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Dyslipidemias; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Practice Guidelines as Topic; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Secondary Prevention; Sulfonamides; Treatment Outcome	2009
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2010, Volume: 10, Issue:1 Topics: Clinical Trials as Topic; Drug Interactions; Dyslipidemias; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2010
Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUP Circulation, 2010, Mar-09, Volume: 121, Issue:9 Topics: Aged; C-Reactive Protein; Cholesterol, LDL; Comorbidity; Double-Blind Method; Dyslipidemias; Early Termination of Clinical Trials; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Myocardial Ischemia; Proportional Hazards Models; Pyrimidines; Risk; Risk Factors; Rosuvastatin Calcium; Sex Factors; Stroke; Sulfonamides; Treatment Outcome	2010
Drug safety evaluation of rosuvastatin. Expert opinion on drug safety, 2011, Volume: 10, Issue:6 Topics: Clinical Trials as Topic; Drug Evaluation; Dyslipidemias; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides	2011
A review of time courses and predictors of lipid changes with fenofibric acid-statin combination. Cardiovascular drugs and therapy, 2012, Volume: 26, Issue:3 Topics: Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2012
Rosuvastatin and diabetes: when the evidences talk. Cardiovascular & hematological agents in medicinal chemistry, 2013, Volume: 11, Issue:2 Topics: Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2013
[Efficacy of lipid correcting therapy with the use of rosuvastatin]. Kardiologiia, 2005, Volume: 45, Issue:6 Topics: Atherosclerosis; Dyslipidemias; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2005
Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation. Preventive cardiology, 2005,Fall, Volume: 8, Issue:4 Topics: Atorvastatin; Comorbidity; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Failure, Chronic; Kidney Transplantation; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2005
[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:2 Pt 1 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Graft Rejection; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Failure, Chronic; Liver Transplantation; Middle Aged; Pravastatin; Primary Prevention; Prospective Studies; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors	2006
Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study. Vascular health and risk management, 2007, Volume: 3, Issue:4 Topics: Atorvastatin; Azetidines; Cholesterol, HDL; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Niacin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2007

Trials

46 trial(s) available for fluorobenzenes and Dyslipidemia

Article	Year
Comparison of switch to the highest dose of rosuvastatin vs. add-on nicotinic acid vs. add-on fenofibrate for mixed dyslipidaemia. International journal of clinical practice, 2013, Volume: 67, Issue:5 Topics: Cholesterol, HDL; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Niacin; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2013
Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial. European journal of clinical investigation, 2013, Volume: 43, Issue:7 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Apolipoproteins B; Atherosclerosis; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Niacin; Pilot Projects; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors	2013
A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease. Clinical therapeutics, 2013, Volume: 35, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides; Triglycerides; Young Adult	2013
Lipid-modulating treatments for mixed dyslipidemia increase HDL-associated phospholipase A2 activity with differential effects on HDL subfractions. Lipids, 2013, Volume: 48, Issue:10 Topics: Aged; Blood Chemical Analysis; Delayed-Action Preparations; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Male; Middle Aged; Niacin; Phospholipases A2; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2013
Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus. Arteriosclerosis, thrombosis, and vascular biology, 2014, Volume: 34, Issue:2 Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kinetics; Male; Middle Aged; Models, Biological; Niacin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides; Up-Regulation; Western Australia	2014
Combining rosuvastatin with angiotensin-receptor blockers of different PPARγ-activating capacity: effects on high-density lipoprotein subfractions and associated enzymes. Angiology, 2015, Volume: 66, Issue:1 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Angiotensin II Type 1 Receptor Blockers; Aryldialkylphosphatase; Benzimidazoles; Benzoates; Biomarkers; Biphenyl Compounds; Cholesterol, HDL; Drug Therapy, Combination; Dyslipidemias; Female; Fluorobenzenes; Greece; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Imidazoles; Irbesartan; Lipoproteins, HDL; Male; Middle Aged; PPAR gamma; Prediabetic State; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Telmisartan; Tetrazoles; Treatment Outcome	2015
Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin. Cardiovascular therapeutics, 2014, Volume: 32, Issue:3 Topics: Aged; Atherosclerosis; Atorvastatin; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Drug Substitution; Dyslipidemias; Female; Fluorobenzenes; Guideline Adherence; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Societies, Medical; Sulfonamides; Time Factors; Treatment Outcome	2014
The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology, 2015, Volume: 66, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol, LDL; Dyslipidemias; Elective Surgical Procedures; Ezetimibe; Female; Fluorobenzenes; Glomerular Filtration Rate; Greece; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Vascular Surgical Procedures	2015
More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. Transplantation, 2014, Jun-27, Volume: 97, Issue:12 Topics: Aged; Biomarkers; Cytochrome P-450 CYP3A; Drug Interactions; Drug Substitution; Dyslipidemias; Everolimus; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indoles; Kidney Transplantation; Lipids; Male; Middle Aged; Norway; Phenotype; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sirolimus; Sulfonamides; Treatment Outcome	2014
Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling. Scandinavian journal of clinical and laboratory investigation, 2014, Volume: 74, Issue:4 Topics: Aged; Aged, 80 and over; Apolipoprotein A-I; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Male; Middle Aged; Pyrimidines; Pyrroles; Quinolines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2014
Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia. Cardiovascular therapeutics, 2014, Volume: 32, Issue:4 Topics: Aged; Apolipoprotein B-100; Atorvastatin; Bilirubin; Biomarkers; Dinoprost; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipoproteins, LDL; Male; Middle Aged; Niacin; Oxidative Stress; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Uric Acid	2014
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA, 2014, May-14, Volume: 311, Issue:18 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Azetidines; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2014
[A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease]. Terapevticheskii arkhiv, 2014, Volume: 86, Issue:9 Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Coronary Disease; Dose-Response Relationship, Drug; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Dyslipidemias; Essential Hypertension; Female; Fluorobenzenes; Humans; Hypertension; Hypolipidemic Agents; Lipid Metabolism; Lisinopril; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2014
[Efficacy and safety comparison of different statins in elderly patients]. Zhonghua xin xue guan bing za zhi, 2014, Volume: 42, Issue:11 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides	2014
Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet (London, England), 2015, Aug-01, Volume: 386, Issue:9992 Topics: Adolescent; Adult; Aged; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Denmark; Double-Blind Method; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Netherlands; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Young Adult	2015
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. Clinical drug investigation, 2008, Volume: 28, Issue:10 Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Prospective Studies; Pyrimidines; Pyrroles; Research Design; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome	2008
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis, 2009, Volume: 204, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Biomarkers; Canada; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Puerto Rico; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides; United States	2009
Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes care, 2009, Volume: 32, Issue:6 Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Metabolic Syndrome; Middle Aged; Placebos; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides; White People	2009
Omega-3 fatty acids plus rosuvastatin improves endothelial function in South Asians with dyslipidemia. Vascular health and risk management, 2008, Volume: 4, Issue:6 Topics: Adult; Aged; Asia; Asian People; Cross-Over Studies; Drug Therapy, Combination; Dyslipidemias; Endothelium, Vascular; Fatty Acids, Omega-3; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; New York; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Vasodilation; Vasodilator Agents	2008
Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS (London, England), 2010, Jan-02, Volume: 24, Issue:1 Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Dyslipidemias; Female; Fluorobenzenes; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Viral Load	2010
Pharmacokinetics of rosuvastatin in patients with end-stage kidney disease undergoing peritoneal dialysis. Clinical nephrology, 2009, Volume: 72, Issue:6 Topics: Chromatography, High Pressure Liquid; Dyslipidemias; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2009
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study. Clinical drug investigation, 2010, Volume: 30, Issue:1 Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, VLDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2010
Efficacy and safety of ezetimibe for Japanese patients with dyslipidaemia: The ESSENTIAL Study. Clinical drug investigation, 2010, Volume: 30, Issue:3 Topics: Aged; Anticholesteremic Agents; Asian People; Azetidines; Cholesterol; Clinical Chemistry Tests; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Metabolic Syndrome; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides	2010
Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUP Circulation, 2010, Mar-09, Volume: 121, Issue:9 Topics: Aged; C-Reactive Protein; Cholesterol, LDL; Comorbidity; Double-Blind Method; Dyslipidemias; Early Termination of Clinical Trials; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Myocardial Ischemia; Proportional Hazards Models; Pyrimidines; Risk; Risk Factors; Rosuvastatin Calcium; Sex Factors; Stroke; Sulfonamides; Treatment Outcome	2010
Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients. Nucleosides, nucleotides & nucleic acids, 2010, Volume: 29, Issue:4-6 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Uric Acid	2010
Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study. Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:5-6 Topics: Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2010
Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies. Clinical cardiology, 2010, Volume: 33, Issue:10 Topics: Aged; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2010
Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus. Cardiovascular drugs and therapy, 2011, Volume: 25, Issue:1 Topics: Anticholesteremic Agents; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2011
High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. Lipids, 2011, Volume: 46, Issue:6 Topics: Dyslipidemias; Fatty Acids, Omega-3; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2011
Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis. Current medical research and opinion, 2011, Volume: 27, Issue:5 Topics: Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors	2011
Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study. International journal of clinical practice, 2011, Volume: 65, Issue:6 Topics: Adipokines; Aged; Atorvastatin; Blood Glucose; Cholesterol; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2011
The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:17 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Aryldialkylphosphatase; C-Reactive Protein; Dinoprost; Drug Combinations; Dyslipidemias; Fatty Acids, Omega-3; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Inflammation; Lipids; Male; Middle Aged; Oxidative Stress; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2011
Low-dose rosuvastatin improves arterial stiffness in high-risk Japanese patients with dyslipdemia in a primary prevention group. Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:11 Topics: Aged; Asian People; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Japan; Male; Middle Aged; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors; Vascular Stiffness	2011
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA, 2011, Nov-16, Volume: 306, Issue:19 Topics: Aged; Atorvastatin; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2011
One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Apr-01, Volume: 12, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2012
Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels. Journal of cardiovascular pharmacology and therapeutics, 2012, Volume: 17, Issue:4 Topics: 25-Hydroxyvitamin D 2; Adult; Aged; Calcifediol; Cardiovascular Diseases; Combined Modality Therapy; Dietary Supplements; Drug Therapy, Combination; Dyslipidemias; Fatty Acids, Omega-3; Female; Fenofibrate; Fluorobenzenes; Greece; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2012
Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor. AIDS (London, England), 2012, Sep-10, Volume: 26, Issue:14 Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Fluorobenzenes; France; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Pravastatin; Pyrimidines; Ritonavir; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2012
Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia. Journal of lipid research, 2012, Volume: 53, Issue:11 Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Angiopoietins; Apolipoproteins; Apolipoproteins B; Atorvastatin; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2012
Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. International journal of clinical practice, 2012, Volume: 66, Issue:9 Topics: Apolipoproteins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Fatty Acids, Omega-3; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Male; Medication Adherence; Metabolic Syndrome; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2012
Effects of manidipine plus rosuvastatin versus olmesartan plus rosuvastatin on markers of insulin resistance in patients with impaired fasting glucose, hypertension, and mixed dyslipidemia. Journal of cardiovascular pharmacology and therapeutics, 2013, Volume: 18, Issue:2 Topics: Aged; Blood Glucose; Dihydropyridines; Drug Therapy, Combination; Dyslipidemias; Endpoint Determination; Fasting; Female; Fluorobenzenes; Humans; Hypertension; Imidazoles; Insulin Resistance; Male; Middle Aged; Nitrobenzenes; Piperazines; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Single-Blind Method; Sulfonamides; Tetrazoles; Treatment Outcome	2013
Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology, 2007, Volume: 107, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Dyslipidemias; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2007
[Compared with atorvastatin at the dose of 10 mg per day rosuvastatin was more effective to reach an LDL goal of < 1.00 g/l in high cardiovascular risk patients (ARIANE study)]. Annales de cardiologie et d'angeiologie, 2007, Volume: 56, Issue:2 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides	2007
[Treatment for dyslipidemias in patients with arterial hypertension]. Terapevticheskii arkhiv, 2007, Volume: 79, Issue:4 Topics: Antihypertensive Agents; Cholesterol; Combined Modality Therapy; Drug Therapy, Combination; Dyslipidemias; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipoproteins, HDL; Lipoproteins, LDL; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Russia; Sulfonamides; Treatment Outcome	2007
Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arteriosclerosis, thrombosis, and vascular biology, 2007, Volume: 27, Issue:10 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Apolipoprotein A-I; Apolipoproteins B; Azetidines; Cholesterol; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Lipoprotein(a); Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Phospholipases A2; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides	2007
A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clinical therapeutics, 2007, Volume: 29, Issue:7 Topics: Apolipoproteins; Blood Glucose; Diet; Dyslipidemias; Female; Fluorobenzenes; Humans; Hypolipidemic Agents; Insulin; Lipoproteins; Male; Middle Aged; Patient Compliance; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2007
Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients. Pharmacotherapy, 2008, Volume: 28, Issue:5 Topics: Adult; Aged; Azetidines; Cholesterol, LDL; Colorado; Drug Combinations; Dyslipidemias; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pharmacists; Poverty; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2008

Other Studies

48 other study(ies) available for fluorobenzenes and Dyslipidemia

Article	Year
Factors associated with statin selection among privately insured commercial and Medicare patients. Current medical research and opinion, 2013, Volume: 29, Issue:4 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Comorbidity; Drug Interactions; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insurance, Health; Male; Medicare; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sex Factors; Simvastatin; Sulfonamides; United States; Young Adult	2013
Efficacy and safety of rosuvastatin in late-onset hypogonadism patients with dyslipidaemia. Andrologia, 2014, Volume: 46, Issue:4 Topics: Cholesterol, LDL; Dyslipidemias; Fluorobenzenes; Humans; Hypogonadism; Male; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Testosterone	2014
Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database. European journal of preventive cardiology, 2013, Volume: 20, Issue:6 Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Databases, Factual; Dose-Response Relationship, Drug; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Odds Ratio; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome	2013
Risk of incident diabetes among patients treated with statins: population based study. BMJ (Clinical research ed.), 2013, May-23, Volume: 346 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Odds Ratio; Ontario; Population Surveillance; Pravastatin; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2013
RP-LC simultaneous quantitation of co-administered drugs for (non-insulin dependent) diabetic mellitus induced dyslipidemia in active pharmaceutical ingredient, pharmaceutical formulations and human serum with UV-detector. Clinica chimica acta; international journal of clinical chemistry, 2013, Oct-21, Volume: 425 Topics: Adult; Anticholesteremic Agents; Calibration; Chromatography, Reverse-Phase; Diabetes Mellitus, Type 2; Dyslipidemias; Fluorobenzenes; Healthy Volunteers; Humans; Hypoglycemic Agents; Limit of Detection; Male; Metformin; Pyrimidines; Quality Control; Rosuvastatin Calcium; Sulfonamides; Sulfonylurea Compounds; Ultraviolet Rays	2013
Prevalence and types of persistent dyslipidemia in patients treated with statins. Croatian medical journal, 2013, Volume: 54, Issue:4 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Croatia; Cross-Sectional Studies; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prevalence; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides	2013
Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome. The Annals of pharmacotherapy, 2014, Volume: 48, Issue:1 Topics: Alanine Transaminase; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Drug Resistance; Drug Therapy, Combination; Dyslipidemias; Fatty Liver; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Male; Metabolic Syndrome; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Thiazolidinediones	2014
Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Vascular health and risk management, 2013, Volume: 9 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Cholesterol, LDL; Databases, Factual; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Managed Care Programs; Middle Aged; Multivariate Analysis; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; United States	2013
Beneficial effects of black yeast derived 1-3, 1-6 Beta Glucan-Nichi Glucan in a dyslipidemic individual of Indian origin--a case report. Journal of dietary supplements, 2014, Volume: 11, Issue:1 Topics: beta-Glucans; Biological Products; Cholesterol; Dietary Supplements; Drug Therapy, Combination; Dyslipidemias; Fluorobenzenes; Humans; India; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides; Yeasts	2014
Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events. Clinical therapeutics, 2014, Jan-01, Volume: 36, Issue:1 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Computer Simulation; Drug Substitution; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Middle Aged; Models, Biological; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2014
Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia. The Journal of international medical research, 2014, Volume: 42, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fluorobenzenes; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides; Young Adult	2014
Efficacy of rosuvastatin in achieving target HDL, LDL, triglycerides and total cholesterol levels in type 2 diabetes mellitus (T2DM) with newly diagnosed dyslipidaemia: an open label, nonrandomised, non-interventional and observational study in India. The Journal of the Association of Physicians of India, 2013, Volume: 61, Issue:10 Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides	2013
Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:8 Topics: Adult; Arteriosclerosis; C-Reactive Protein; Carotid Intima-Media Thickness; Cerebral Infarction; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Triglycerides	2014
Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet. Arteriosclerosis, thrombosis, and vascular biology, 2014, Volume: 34, Issue:10 Topics: Animals; Apolipoprotein A-I; Atherosclerosis; Atorvastatin; ATP Binding Cassette Transporter 1; Biological Transport; Cell Line; Cholesterol Esters; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, VLDL; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors	2014
The evolving role of CETP inhibition: beyond HDL cholesterol. Lancet (London, England), 2015, Aug-01, Volume: 386, Issue:9992 Topics: Cholesterol Ester Transfer Proteins; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Pyrroles; Quinolines; Sulfonamides	2015
Dyslipidaemia: Promising results for TA-8995 in TULIP. Nature reviews. Cardiology, 2015, Volume: 12, Issue:8 Topics: Cholesterol Ester Transfer Proteins; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Pyrroles; Quinolines; Sulfonamides	2015
Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia. Current medical research and opinion, 2008, Volume: 24, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chromatography, High Pressure Liquid; Dyslipidemias; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Middle Aged; Pyrimidines; Racial Groups; Rosuvastatin Calcium; Sulfonamides; Tandem Mass Spectrometry	2008
Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. Journal of lipid research, 2010, Volume: 51, Issue:6 Topics: Animals; Cell Line; Cholesterol, LDL; Cricetinae; Dietary Carbohydrates; Dose-Response Relationship, Drug; Drug Resistance; Dyslipidemias; Fluorobenzenes; Fructose; Hepatocyte Nuclear Factor 1-alpha; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Proprotein Convertase 9; Proprotein Convertases; Pyrimidines; RNA, Messenger; Rosuvastatin Calcium; Serine Endopeptidases; Sterol Regulatory Element Binding Protein 2; Sulfonamides; Transcription, Genetic; Transcriptional Activation	2010
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2010, Volume: 10, Issue:2 Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2010
Cost-effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico. Current medical research and opinion, 2010, Volume: 26, Issue:5 Topics: Aged; Azetidines; Cost-Benefit Analysis; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mexico; Middle Aged; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2010
Imperfect pharmacovigilance. Southern medical journal, 2010, Volume: 103, Issue:7 Topics: Adverse Drug Reaction Reporting Systems; Aged; Dyslipidemias; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Product Surveillance, Postmarketing; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Thrombocytopenia	2010
Rosuvastatin-induced thrombocytopenia. Southern medical journal, 2010, Volume: 103, Issue:7 Topics: Aged; Dyslipidemias; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Thrombocytopenia	2010
Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS). The Canadian journal of cardiology, 2010, Volume: 26, Issue:9 Topics: Aged; Atorvastatin; Canada; Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studies; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medicine; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Prevalence; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2010
Letter by Wells and Eisenberg regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: Circulation, 2010, Dec-07, Volume: 122, Issue:23 Topics: C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Dyslipidemias; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2010
Letter by Vos et al regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Interve Circulation, 2010, Dec-07, Volume: 122, Issue:23 Topics: C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Dyslipidemias; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2010
Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Feb-01, Volume: 52, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol; Cohort Studies; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Serum; Sulfonamides	2011
Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemia. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2011, Volume: 17, Issue:3 Topics: Adult; Antiretroviral Therapy, Highly Active; Dyslipidemias; Fluorobenzenes; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Liver Transplantation; Male; Pyrimidines; Rhabdomyolysis; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides	2011
Was the low-density lipoprotein cholesterol level really elevated? Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2011, Volume: 17, Issue:10 Topics: Dyslipidemias; Fluorobenzenes; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Liver Transplantation; Male; Pyrimidines; Rhabdomyolysis; Sulfonamides	2011
Rhabdomyolysis in an HIV-infected patient with impaired renal function concomitantly treated with rosuvastatin and lopinavir/ritonavir. Antiviral therapy, 2011, Volume: 16, Issue:3 Topics: Anti-HIV Agents; Drug Therapy, Combination; Dyslipidemias; Fluorobenzenes; HIV Infections; HIV-1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lopinavir; Male; Middle Aged; Pyrimidines; Pyrimidinones; Renal Insufficiency; Rhabdomyolysis; Ritonavir; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2011
Low-density lipoprotein cholesterol goal attainment among Malaysian dyslipidemic patients. The Southeast Asian journal of tropical medicine and public health, 2011, Volume: 42, Issue:2 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Logistic Models; Malaysia; Male; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2011
Therapy and clinical trials: aggressive statin therapy versus combined and emerging approaches. Current opinion in lipidology, 2011, Volume: 22, Issue:4 Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Clinical Trials as Topic; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2011
Prevalence of low LDL-cholesterol levels and elevated high-sensitivity C-reactive protein levels in apparently healthy Korean adults. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2012, Volume: 22, Issue:12 Topics: Asian People; Blood Pressure; C-Reactive Protein; Cholesterol, LDL; Cohort Studies; Dyslipidemias; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Male; Middle Aged; Pyrimidines; Republic of Korea; Rosuvastatin Calcium; Sulfonamides; Surveys and Questionnaires	2012
Rosuvastatin-induced pemphigoid. BMJ case reports, 2012, May-08, Volume: 2012 Topics: Biopsy; Dyslipidemias; Female; Fluorescent Antibody Technique; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pemphigoid, Bullous; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2012
Clinical equivalence of proprietary and generic atorvastatin in lipid clinic patients. The Canadian journal of cardiology, 2013, Volume: 29, Issue:4 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Canada; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Drugs, Generic; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Therapeutic Equivalency; Treatment Outcome; Triglycerides	2013
Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain. Journal of medical economics, 2012, Volume: 15 Suppl 1 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drugs, Generic; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Markov Chains; Middle Aged; Primary Prevention; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Spain; Sulfonamides	2012
Rosuvastatin and ciprofibrate in the treatment of dyslipidemia in patients with HIV. Arquivos brasileiros de cardiologia, 2012, Volume: 99, Issue:5 Topics: Adult; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; Cholesterol; Dyslipidemias; Female; Fibric Acids; Fluorobenzenes; HIV Infections; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Statistics, Nonparametric; Sulfonamides; Treatment Outcome; Triglycerides	2012
Statins use and female lung cancer risk in Taiwan. The Libyan journal of medicine, 2012, 12-27, Volume: 7, Issue:1 Topics: Adult; Aged; Dyslipidemias; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Lung Neoplasms; Middle Aged; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Taiwan; Time Factors	2012
Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia. Atherosclerosis, 2006, Volume: 185, Issue:1 Topics: Animals; Apolipoproteins B; Cells, Cultured; Chromatography, Gel; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Dyslipidemias; Electrophoresis, Polyacrylamide Gel; Fluorobenzenes; Hepatocytes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Liver; Male; Mesocricetus; Metabolic Syndrome; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2006
Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan. Atherosclerosis, 2006, Volume: 184, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Blotting, Western; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyslipidemias; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinases; Phosphorylation; Pyrimidines; Renin-Angiotensin System; Rosuvastatin Calcium; Scavenger Receptors, Class E; Sulfonamides; Tetrazoles	2006
Rosuvastatin as treatment for non alcoholic steatohepatitis (NASH) and highly active antiretroviral therapy (HAART)-dyslipidaemia: new treatment for global dangers. Medical hypotheses, 2006, Volume: 66, Issue:2 Topics: Antiretroviral Therapy, Highly Active; Dyslipidemias; Fluorobenzenes; Hepatitis; Humans; Lipoproteins, LDL; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2006
Rosuvastatin: a safe and effective treatment for dyslipidaemia associated with non-alcoholic steatohepatitis (NASH). Scandinavian journal of gastroenterology, 2006, Volume: 41, Issue:5 Topics: Dyslipidemias; Fluorobenzenes; Hepatitis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Rosuvastatin Calcium; Steatitis; Sulfonamides	2006
Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. The Journal of clinical psychiatry, 2006, Volume: 67, Issue:12 Topics: Adult; Antipsychotic Agents; Cardiovascular Diseases; Dyslipidemias; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Psychotic Disorders; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Schizophrenia; Sulfonamides; Treatment Outcome	2006
Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice. British journal of pharmacology, 2007, Volume: 151, Issue:3 Topics: Animals; Aorta; Atherosclerosis; Blood Glucose; Body Weight; Cell Line; Dyslipidemias; Fluorobenzenes; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Leptin; Lipids; Lipoproteins, LDL; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Obese; Obesity; PPAR gamma; Pyrimidines; Receptors, LDL; Reverse Transcriptase Polymerase Chain Reaction; Rosuvastatin Calcium; Sulfonamides; Superoxide Dismutase	2007
The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment. Platelets, 2008, Volume: 19, Issue:2 Topics: Adult; Blood Platelets; Cell Size; Dietary Supplements; Dyslipidemias; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2008
Are HIV positive patients resistant to statin therapy? Lipids in health and disease, 2007, Oct-24, Volume: 6 Topics: Cholesterol; Drug Resistance, Multiple, Viral; Dyslipidemias; Female; Fluorobenzenes; HIV Infections; HIV Seropositivity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides	2007
Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice. European heart journal, 2008, Volume: 29, Issue:1 Topics: Animals; Blood Pressure; Dyslipidemias; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Mice; Mice, Obese; PPAR gamma; Pyrimidines; Receptors, LDL; Rosuvastatin Calcium; Sulfonamides	2008
[Inflammation, atherosclerosis, classic cardiovascular risk factors, biostatistics, clinical significance. Where are we?]. Revista espanola de cardiologia, 2007, Volume: 60, Issue:12 Topics: Acute Coronary Syndrome; Atherosclerosis; Biometry; Dyslipidemias; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Inflammation; Metformin; Oxidative Stress; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Tumor Necrosis Factor-alpha	2007
[Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia]. Revista espanola de cardiologia, 2007, Volume: 60, Issue:12 Topics: Analysis of Variance; Dyslipidemias; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Inflammation; Interleukin-6; Metformin; Middle Aged; Oxidative Stress; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tumor Necrosis Factor-alpha	2007